To identify the tumor intrinsic factors that are associated with responsiveness to cancer immunotherapy, we performed genome-wide CRISPR-Cas9 loss-of-function screens of cancer cells using mice bearing human immune system and identified TPST2 as a therapeutic target to enhance anti-PD1 efficacy. The gene discussed is TPST2; the disease is cancer.